Affimed N.V. (AFMD) Up 10.10% for August 4

Equities Staff  |

Today, Affimed N.V. (NASDAQ:AFMD) gained $0.3 to end the day Thursday at $3.27.

The company started at $3.00 and shares fluctuated between $3.27 and $2.97 with 1,555,698 shares trading hands.

Affimed N.V. is averaging 674,427 shares traded over the last 30 days. They have shed 46.20% YTD.

Affimed N.V. anticipates its next earnings on 2022-08-11.

For technical charts, analysis, and more on Affimed N.V. visit the company profile.

About Affimed N.V.

Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE®) molecules, which use patients' immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, New York, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients' lives.

To get more information on Affimed N.V. and to follow the company's latest updates, you can visit the company's profile page here: Affimed N.V.'s Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation

Market Movers

Sponsored Financial Content